Patents Represented by Attorney Eric K. Voelk

Find this attorney in the Justia Lawyer Directory

  • Integrase inhibitors
    Patent number: 8008287
    Abstract: Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: August 30, 2011
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Salman Y. Jabri, Haolun Jin, Rachael A. Lansdown, Samuel E. Metobo, Michael R. Mish, Richard M. Pastor
  • Pharmaceutical solutions of modafinil compounds
    Patent number: 6919378
    Abstract: Pharmaceutical compositions of modafinil compounds, including pharmaceutical, non-aqueous compositions of modafinil compounds in organic solvents and pharmaceutical compositions of a modafinil compound in solid dispersions, are disclosed, along with their use in the treatment of diseases.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: July 19, 2005
    Assignee: Cephalon, Inc.
    Inventors: Martin J. Jacobs, Bradley T. McIntyre, Alpa Parikh, Piyush R. Patel
  • Substituted thioacetamides
    Patent number: 6670358
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: December 30, 2003
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Matthew S. Miller, Rabindranath Tripathy, Jeffry L. Vaught
  • Particle-forming compositions containing fused pyrrolocarbazoles
    Patent number: 6660729
    Abstract: A non-aqueous, particle-forming, fused pyrrolocarbazole-containing composition is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides greatly improved bioavailability of orally administered fused pyrrolocarbazole compounds.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: December 9, 2003
    Assignee: Cephalon, Inc.
    Inventors: David A. Dickason, Piyush R. Patel, Vincent Corvari, Efraim Shek, Joseph L. Herman, Jeffry M. Skell
  • Isomeric fused pyrrolocarbazoles and isoindolones
    Patent number: 6635669
    Abstract: The present invention is directed to novel fused pyrrolocarbazoles and isoindolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: October 21, 2003
    Assignee: Cephalon, Inc.
    Inventor: Robert L. Hudkins
  • Selected fused pyrrolocarbazoles
    Patent number: 6630500
    Abstract: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: October 7, 2003
    Assignee: Cephalon, Inc.
    Inventors: Diane E. Gingrich, Robert L. Hudkins
  • Substituted thioacetamides
    Patent number: 6492396
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: December 10, 2002
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Jeffry L. Vaught, Matthew S. Miller
  • Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
    Patent number: 6488164
    Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: December 3, 2002
    Assignee: Cephalon, Inc.
    Inventors: Matthew S. Miller, Thomas E. Scammell
  • Pharmaceutical solutions of modafinil compounds
    Patent number: 6489363
    Abstract: Pharmaceutical compositions of modafinil compounds, and pharmaceutical, non-aqueous compositions of modafinil compounds in organic solvents are disclosed, along with their use in the treatment of diseases.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: December 3, 2002
    Assignee: Cephalon, Inc.
    Inventors: Martin J. Jacobs, Bradley T. McIntyre, Piyush R. Patel
  • Compositions including modafinil for treatment of eating disorders and for appetite stimulation
    Patent number: 6455588
    Abstract: Modafinil is effective in improving symptoms of eating disorders or in stimulating appetite.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: September 24, 2002
    Assignee: Cephalon, Inc.
    Inventors: Thomas E. Scammell, Matthew S. Miller
  • Heterocyclic substituted pyrazolones
    Patent number: 6455525
    Abstract: The present invention is directed to novel heterocyclic substituted pyrazolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: September 24, 2002
    Assignee: Cephalon, Inc.
    Inventors: Jasbir Singh, Rabindranath Tripathy
  • Isomeric fused pyrrolocarbazoles and isoindolones
    Patent number: 6399780
    Abstract: The present invention is directed to novel fused pyrrolocarbazoles and isoindolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: June 4, 2002
    Assignee: Cephalon, Inc.
    Inventor: Robert L. Hudkins
  • Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
    Patent number: 6346548
    Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: February 12, 2002
    Assignee: Cephalon, Inc.
    Inventors: Matthew S. Miller, Thomas E. Scammell
  • Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
    Patent number: 6329550
    Abstract: The present application relates to novel aminomalonamides of the formula and pharmaceutical composition thereof which are useful for inhibiting matrix metalloproteinases.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: December 11, 2001
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Alan M. Warshawsky, Michael J. Janusz
  • Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl) benzamides useful for the treatment of allergic diseases
    Patent number: 6297259
    Abstract: The present invention relates to novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide derivatives of the formula stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: October 2, 2001
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: George P. Maynard, John M. Kane, Larry D. Bratton, Elizabeth M. Kudlacz
  • Difluoro statone analogs
    Patent number: 6114380
    Abstract: This invention relates to novel difluoro statone analogs, to the processes and intermediates useful for their preparation and to their use as anti-viral agents.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: September 5, 2000
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Daniel Schirlin, Viviane Van Dorsselaer, Celine Tarnus
  • Pharmaceutical formulations comprising polythiourea and methods of use thereof
    Patent number: 6086864
    Abstract: The oligomers of the present invention are polythioureas having 3 to 50 recurring units derived from aromatic diamines substituted with anionic groups, and having a number average molecular weight of less than 10,000. These oligomers are water-soluble, preferably have a rigid backbone, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of AIDS.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: July 11, 2000
    Assignees: Merrell Pharmaceuticals Inc., The Dow Chemical Co.
    Inventors: Michael J. Mullins, William A. Fordyce, William J. Kruper, Norton P. Peet, Alan D. Cardin
  • Narrow poly-and-mono-dispersed anionic oligomers, and their uses, formulations and processes
    Patent number: 6013251
    Abstract: The narrow poly- or mono-dispersed oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a recurring unit of from 3 to 50. These oligomers are water-soluble, preferably have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The narrow poly- or mono-dispersed oligomers are useful for the treatment and/or diagnosis of AIDS and/or ARC or HSV.
    Type: Grant
    Filed: April 1, 1997
    Date of Patent: January 11, 2000
    Assignees: The Dow Chemical Co., Merrell Pharmaceuticals Inc.
    Inventors: Alan D. Cardin, William A. Fordyce, Michael J. Mullins, Thomas A. Chamberlin, Michael J. Fazio
  • Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide disulfide derivatives
    Patent number: 6013645
    Abstract: The present invention relates certain mercaptoacetylamide disulfide derivatives of the formula ##STR1## useful in treating patients suffering from hypertriglyceridemia, atherosclerosis and hypercholestrolemia.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: January 11, 2000
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Gary A. Flynn, John F. French, Richard C. Dage
  • Narrow poly- and mono-dispersed anionic oligomers
    Patent number: 5986044
    Abstract: The narrow poly- or mono-dispersed oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a recurring unit of from 3 to 50. These oligomers are water-soluble, preferably have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The narrow poly- or mono-dispersed oligomers are useful for the treatment and/or diagnosis of AIDS and/or ARC or HSV.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: November 16, 1999
    Assignees: The Dow Chemical Co., Merrell Pharmaceuticals Inc.
    Inventors: Alan D. Cardin, Michael J. Mullins, William A. Fordyce, Thomas A. Chamberlin, Michael J. Fazio